NCT05081349View on ClinicalTrials.gov

Hydoxycarbamide and L-Carnitine Therapy in Sickle Cell Anemia

PHASE4CompletedINTERVENTIONAL
Enrollment

91

Participants

Timeline

Start Date

January 10, 2017

Primary Completion Date

June 10, 2020

Study Completion Date

July 10, 2021

Conditions
Sickle Cell Disease
Interventions
DRUG

Hydroxycarbamide 500 Mg Oral Capsule+L-Carnitine

Combination therapy

DRUG

Hydroxycarbamide 500 Mg Oral Capsule

Single agent

DRUG

L-Carnitine, 250 Mg Oral Capsule

single agent

Trial Locations (1)

71515

Safaa A A Khaled, Asyut

All Listed Sponsors
lead

Assiut University

OTHER

NCT05081349 - Hydoxycarbamide and L-Carnitine Therapy in Sickle Cell Anemia | Biotech Hunter | Biotech Hunter